Hinge Bio
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
863 Mitten Rd Ste 100L, Burlingame, Cali...Phone Number
(650) 488-7070Website
www.hingebio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Hinge Bio
Hinge Bio, Inc. is a biotechnology company focused on taking antibodies to the next dimension with their revolutionary GEM-DIMER Platform. This platform enables the development of a new class of therapeutics that offer enhanced activity and unprecedented degrees of multivalency and multispecificity, leading to superior safety and efficacy in treating diseases. The company is led by a highly experienced team dedicated to delivering successful drug development outcomes and is actively seeking individuals passionate about advancing the next generation of therapeutics. Hinge Bio has been making strides in presenting preclinical data and expanding its senior management team to drive its innovative GEM-DIMER Programs towards clinical development.Explore more
Hinge Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hinge Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Hinge Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Hinge Bio has new funding data
Check if Hinge Bio has recently received funding, and reach out quickly before it becomes old news!
Check out if Hinge Bio is spiking on competitors!
Earning: See what the market has to say on Hinge Bio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Hinge Bio
Click to see if Hinge Bio had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Hinge Bio launches new products
Recommended Actions
Reach out to Masked Content who joined Hinge Bio as Masked Content
Find 3 more new buyers
Compare Similar Companies to Hinge Bio
Compare insights from companies similar to Hinge Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Hinge Bio
<$5M
11-50
Private
$30M
2015
MS
Miriam SiekevitzGeneral Counsel & Chief Administrative Officer
Company Profile Activity
Activity Insights
Hinge Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Hinge Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Hinge Bio.
Hinge Bio financials insights
Gather financial insights about Hinge Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$30M
Hinge Bio Tech Stack
A closer look at the technologies used by Hinge Bio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Research & Development, Intellectual Property, Medical Research, Pharmaceuticals
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Hinge Bio News & Media
Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis
Phase 1 trial to investigate novel multi-specific HB2198 to treat B cell-mediated autoimmune disorders by targeting both CD19 and CD20 plus enhanced immune cell engagement via dual Fc domains Phase 1 trial to investigate novel multi-specific HB2198 to treat B cell-mediated autoimmune disorders by targeting both CD19 and CD20 plus enhanced immune cell engagement via dual Fc domainsHinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases
Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional payments for other indications; includes contingent R&D investment, tiered sales royalties, and a portion of investment to global development. Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional payments for other indications; includes contingent R&D investment, tiered sales royalties, and a portion of investmentHinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports
Paul Brunetta, M.D., joins as Chief Medical Officer; Kristen Quigley joins as Chief Clinical Operations Officer; Alpana Naresh, Ph.D., joins as Vice President and Head, CMC Strategy and ManufacturingHinge Bio Raises $30 Million Series A’ Financing to Develop Next-Generation Therapies via its Proprietary GEM-DIMER Platform
Funding will support the development of Company’s lead product candidate for autoimmune disease as well as novel constructs to treat other indications with significant unmet need. Funding will support the development of Company’s lead product candidate for autoimmune disease as well as novel constructs to treat other indications with significant unmet need.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Hinge Bio
Sign Up For FreeTo access detailed company insights
Hinge Bio, Inc. is a biotechnology company focused on taking antibodies to the next dimension with their revolutionary GEM-DIMER Platform. This platform enables the development of a new class of therapeutics that offer enhanced activity and unprecedented degrees of multivalency and multispecificity, leading to superior safety and efficacy in treati... Read More
